helsinn therapeutics (u.s.), inc.

1140 us highway 22, ste. 101
bridgewater, new jersey 08807

NYS Entity Status
ACTIVE

NYS Filing Date
NOVEMBER 12, 2013

NYS DOS ID#
4485134

County
NEW YORK

Jurisdiction
DELAWARE

Registered Agent
NONE

NYS Entity Type
FOREIGN BUSINESS CORPORATION

Name History
2013 - HELSINN THERAPEUTICS (U.S.), INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • New Jersey Sues Insys Over Opioid Painkiller
    Thursday Oct 5, 2017

    New Jersey’s attorney general filed a lawsuit Thursday against drugmaker Insys Therapeutics Inc., claiming it fraudulently marketed a powerful painkiller for widespread use that was intended to treat serious cancer pain.

    Source: The Wall Street Journal: U.S. Business
  • “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
    By Ben Fidler - Wednesday Jun 7, 2017

    Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]

    Source: Xconomy New York
  • United Therapeutics in Settlement Talks With Justice Department
    Thursday Jul 27, 2017

    United Therapeutics has set aside $210 million for a possible settlement of a U.S. Justice Department investigation of whether the company’s contributions to patient-assistance charity groups violate federal laws against kickbacks and false claims.

    Source: The Wall Street Journal: U.S. Business
  • Economic Trends: To Understand Rising Inequality, Consider the Janitors at Two Top Companies, Then and Now
    By NEIL IRWIN - Sunday Sep 3, 2017

    Focusing on core competence and outsourcing the rest has made U.S. companies lean, nimble and productive. It has also left lots of people worse off.

    Source: NYT > Home Page
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York